Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in Type II diabetes

被引:75
作者
Gervaise, N
Garrigue, MA
Lasfargues, G
Lecomte, P
机构
[1] CHU Bretonneau, Endocrine Unit, F-37044 Tours, France
[2] CHU Bretonneau, Biochem Lab, F-37044 Tours, France
关键词
Type II diabetes; triglycerides; apolipoprotein C3; lipoprotein B : C3; cardiovascular risk; macroangiopathy; CHD;
D O I
10.1007/s001250051366
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis. Cardiovascular complications and particularly coronary heart disease are the main causes of morbidity and mortality in Type II (non-insulin-dependent) diabetes mellitus. Some studies have shown that hypertriglyceridaemia in diabetes is an independent cardiovascular risk factor. In the ECTIM study high apolipoprotein C3 and lipoprotein B:C3 concentrations (lipoparticles playing a role in triglyceride metabolism) were associated with myocardial infarction in non-diabetic subjects. Methods. We studied the relations between macroangiopathy and different cardiovascular risk factors and lipid variables in 188 Type II diabetic subjects. Results. Multivariate analysis showed that triglycerides, apo C3 and Lp B:C3, sex, duration of diabetes, microalbuminuria and age were independently associated with macroangiopathy. The study group was divided into quartiles according to apo C3 and Lp B:C3 concentrations: the prevalence of macroangiopathy and coronary heart disease were increased in upper quartiles. Conclusion/interpretation. Triglycerides apo C3 and Lp B:C3 were independent cardiovascular risk markers in our group of Type II diabetic patients.
引用
收藏
页码:703 / 708
页数:6
相关论文
共 34 条
[1]   MECHANISM OF HYPERTRIGLYCERIDEMIA IN HUMAN APOLIPOPROTEIN-(APO)-CIII TRANSGENIC MICE - DIMINISHED VERY LOW-DENSITY-LIPOPROTEIN FRACTIONAL CATABOLIC RATE ASSOCIATED WITH INCREASED APO-CIII AND REDUCED APO-E ON THE PARTICLES [J].
AALTOSETALA, K ;
FISHER, EA ;
CHEN, XL ;
CHAJEKSHAUL, T ;
HAYEK, T ;
ZECHNER, R ;
WALSH, A ;
RAMAKRISHNAN, R ;
GINSBERG, HN ;
BRESLOW, JL .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (05) :1889-1900
[2]   IDENTIFICATION OF APO-B-CONTAINING LIPOPROTEIN FAMILIES IN NIDDM [J].
ALAUPOVIC, P ;
BARD, JM ;
TAVELLA, M ;
SHAFER, D .
DIABETES, 1992, 41 :18-25
[3]   Transcriptional control of triglyceride metabolism: Fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR [J].
Auwerx, J ;
Schoonjans, K ;
Fruchart, JC ;
Staels, B .
ATHEROSCLEROSIS, 1996, 124 :S29-S37
[4]  
BENNETT PH, 1995, AM J KIDNEY DIS, V25, P107
[5]  
BLANKENHORN DH, 1993, CIRCULATION, V88, P2762
[6]  
CLAVEY V, 1991, ANN ENDOCRINOL-PARIS, V52, P459
[7]   MODULATION OF LIPOPROTEIN B BINDING TO THE LDL RECEPTOR BY EXOGENOUS LIPIDS AND APOLIPOPROTEIN-CI, APOLIPOPROTEIN-CII, APOLIPOPROTEIN-CIII, AND APOLIPOPROTEIN-E [J].
CLAVEY, V ;
LESTAVELDELATTRE, S ;
COPIN, C ;
BARD, JM ;
FRUCHART, JC .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (07) :963-971
[8]  
DESILVA HV, 1994, J BIOL CHEM, V269, P2324
[9]   HYPERTRIGLYCERIDEMIA AS A RISK FACTOR OF CORONARY HEART-DISEASE MORTALITY IN SUBJECTS WITH IMPAIRED GLUCOSE-TOLERANCE OR DIABETES - RESULTS FROM THE 11-YEAR FOLLOW-UP OF THE PARIS PROSPECTIVE-STUDY [J].
FONTBONNE, A ;
ESCHWEGE, E ;
CAMBIEN, F ;
RICHARD, JL ;
DUCIMETIERE, P ;
THIBULT, N ;
WARNET, JM ;
CLAUDE, JR ;
ROSSELIN, GE .
DIABETOLOGIA, 1989, 32 (05) :300-304
[10]  
Fredenrich A, 1998, DIABETES METAB, V24, P490